These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 24460276)

  • 1. Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
    Li FY; Ren XB; Xie XY; Zhang J
    Asian Pac J Cancer Prev; 2013; 14(12):7203-6. PubMed ID: 24460276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship of platinum resistance and ERCC1 protein expression in epithelial ovarian cancer.
    Steffensen KD; Waldstrøm M; Jakobsen A
    Int J Gynecol Cancer; 2009 Jul; 19(5):820-5. PubMed ID: 19574766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.
    Tang N; Lyu D; Zhang Y; Liu H
    BMC Womens Health; 2017 Jun; 17(1):43. PubMed ID: 28623887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
    Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
    Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
    Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
    Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
    Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
    Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
    Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
    Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
    Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer.
    Lin K; Ye D; Xie X
    Int J Gynecol Cancer; 2008; 18(5):1007-12. PubMed ID: 18081788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of excision repair cross-complementation group 1 (ERCC1) in patients with small cell lung cancer (SCLC) receiving platinum-based chemotherapy: evidence from meta-analysis.
    Yang Y; Luo X; Yang N; Feng R; Xian L
    PLoS One; 2014; 9(11):e111651. PubMed ID: 25375151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis.
    Zhang C; Gao S; Hou J
    Int J Biol Markers; 2020 Dec; 35(4):12-19. PubMed ID: 33126828
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of ERCC1 and Hormonal Receptor Expression in Ovarian Cancer.
    El-Moniem Elrawi DA; El Khodary AI; Nassar HR; Darwish AD; Khorshed EN
    J Med Invest; 2020; 67(3.4):391-398. PubMed ID: 33148925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The protein expression of ERCC1 and survivin in epithelial ovarian carcinoma and their clinical significance].
    Xie C; Yin RT; Li YL; Kang DY; Xu L; Yang KX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Jan; 42(1):86-9. PubMed ID: 21355309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.
    Wei KK; Jiang L; Wei YY; Wang YF; Qian XK; Dai Q; Guan QL
    Tumour Biol; 2014 Sep; 35(9):8721-31. PubMed ID: 24870596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis of excision repair cross complementary gene 1 (ERCC1) expression and platinum chemosensitivity in patients with ovarian cancer.
    Wu J; Li R; Chen X; Chen C; Chen H; Ma B
    Ann Palliat Med; 2020 Sep; 9(5):3428-3435. PubMed ID: 33065793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1-positive circulating tumor cells in the blood of ovarian cancer patients as a predictive biomarker for platinum resistance.
    Kuhlmann JD; Wimberger P; Bankfalvi A; Keller T; Schöler S; Aktas B; Buderath P; Hauch S; Otterbach F; Kimmig R; Kasimir-Bauer S
    Clin Chem; 2014 Oct; 60(10):1282-9. PubMed ID: 25015375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of excision repair cross complementation group 1 rs2298881 in patients with gastric cancer receiving platinum-based chemotherapy: A PRISMA-compliant meta-analysis.
    Lv Y; Xu M; Sun Y; Liu Y; Zhao L; Liu X; Li Z; Shi G; Jia J; Bi L; Ma N; Zhang X; Qi C
    Medicine (Baltimore); 2021 Aug; 100(33):e26850. PubMed ID: 34414935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.
    Zhang Y; Cao S; Zhuang C; Chen J; Chen X; Sun H; Lin S; Lin B
    J Ovarian Res; 2021 Jun; 14(1):80. PubMed ID: 34148553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
    Wu X; Lu W; Jiang C; Zhang D; Zhang W; Cui Y; Zhuo Z; Mei H; Wang Y; Zhang M; Chen S
    PLoS One; 2023; 18(5):e0284825. PubMed ID: 37141338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.